X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SANOFI INDIA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SANOFI INDIA PANACEA BIOTECH/
SANOFI INDIA
 
P/E (TTM) x 169.7 33.7 502.8% View Chart
P/BV x 3.8 6.4 58.6% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 PANACEA BIOTECH   SANOFI INDIA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
SANOFI INDIA
Dec-16
PANACEA BIOTECH/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1494,560 3.3%   
Low Rs824,400 1.9%   
Sales per share (Unadj.) Rs84.11,028.5 8.2%  
Earnings per share (Unadj.) Rs-18.3129.0 -14.2%  
Cash flow per share (Unadj.) Rs-6.7186.0 -3.6%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs83.7753.6 11.1%  
Shares outstanding (eoy) m61.2523.03 266.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.44.4 31.5%   
Avg P/E ratio x-6.334.7 -18.2%  
P/CF ratio (eoy) x-17.224.1 -71.6%  
Price / Book Value ratio x1.45.9 23.2%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m7,074103,174 6.9%   
No. of employees `0002.83.6 75.9%   
Total wages/salary Rs m1,4493,592 40.3%   
Avg. sales/employee Rs Th1,874.16,537.7 28.7%   
Avg. wages/employee Rs Th527.0991.4 53.2%   
Avg. net profit/employee Rs Th-407.7819.8 -49.7%   
INCOME DATA
Net Sales Rs m5,15423,686 21.8%  
Other income Rs m100708 14.1%   
Total revenues Rs m5,25424,394 21.5%   
Gross profit Rs m-7665,281 -14.5%  
Depreciation Rs m7111,313 54.2%   
Interest Rs m1,50315 10,020.0%   
Profit before tax Rs m-2,8814,661 -61.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m171,691 1.0%   
Profit after tax Rs m-1,1212,970 -37.8%  
Gross profit margin %-14.922.3 -66.7%  
Effective tax rate %-0.636.3 -1.6%   
Net profit margin %-21.812.5 -173.5%  
BALANCE SHEET DATA
Current assets Rs m3,81015,673 24.3%   
Current liabilities Rs m8,3656,678 125.3%   
Net working cap to sales %-88.438.0 -232.7%  
Current ratio x0.52.3 19.4%  
Inventory Days Days15676 204.9%  
Debtors Days Days6722 301.3%  
Net fixed assets Rs m14,4808,098 178.8%   
Share capital Rs m61230 26.6%   
"Free" reserves Rs m90317,088 5.3%   
Net worth Rs m5,12717,356 29.5%   
Long term debt Rs m5,8320-   
Total assets Rs m19,43325,400 76.5%  
Interest coverage x-0.9311.7 -0.3%   
Debt to equity ratio x1.10-  
Sales to assets ratio x0.30.9 28.4%   
Return on assets %2.011.8 16.7%  
Return on equity %-21.917.1 -127.8%  
Return on capital %3.626.9 13.5%  
Exports to sales %24.524.5 100.1%   
Imports to sales %10.228.0 36.4%   
Exports (fob) Rs m1,2645,801 21.8%   
Imports (cif) Rs m5256,627 7.9%   
Fx inflow Rs m1,5397,145 21.5%   
Fx outflow Rs m9426,846 13.8%   
Net fx Rs m597299 199.7%   
CASH FLOW
From Operations Rs m5993,226 18.6%  
From Investments Rs m-438-1,555 28.2%  
From Financial Activity Rs m-303-1,818 16.6%  
Net Cashflow Rs m-141-147 96.1%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.6 14.4 4.2%  
FIIs % 1.3 14.6 8.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 15,184 67.6%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 20, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS